PMID- 32250311
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20210510
IS  - 1875-8908 (Electronic)
IS  - 1387-2877 (Linking)
VI  - 75
IP  - 2
DP  - 2020
TI  - A New Neurovascular Panel Discriminates Between Patients with Type 2 Diabetes 
      Mellitus with Cognitive Impairment and Cognitive Impairment Alone.
PG  - 461-469
LID - 10.3233/JAD-200095 [doi]
AB  - BACKGROUND: Recent studies showed that type 2 diabetes mellitus (T2DM) may 
      increase the risk of cognitive impairment, but there are few biomarkers to 
      diagnostically discriminate T2DM-associated cognitive impairment and cognitive 
      impairment alone. In this study, we assessed certain cytokines involved in 
      inflammation and vascular diseases and identified special panel of cytokines that 
      could differentiate between T2DM and cognitive impairment. OBJECTIVE: To 
      investigate associations and differences between T2DM and cognitive impairment by 
      cytokines analysis. METHODS: A total of 264 participants were recruited, their 
      blood samples were collected, and plasma and serum were separated and stored at - 
      80 degrees C until the assessment of amyloid-beta (Abeta)42, Abeta40 and 8 kinds of cytokines by 
      Luminex multiplex assays. RESULTS: Plasma Abeta40 is higher whereas Abeta42/40 ratio is 
      lower in cognitive impairment and T2DM-associated cognitive impairment compared 
      to other groups. As compared to health control, YKL-40 level was upregulated in 
      cognitive impairment, PRGN was downregulated in T2DM associated cognitive 
      impairment, OPN was substantially decreased in T2DM, and IL-6 was elevated in 
      cognitive impairment and T2DM-associated cognitive impairment. Interestingly, 
      VEGF and S100B were induced in T2DM when compared with cognitive impairment, and 
      NSE level in T2DM-associated cognitive impairment is significantly lower than in 
      T2DM or cognitive impairment. CONCLUSION: Abeta42, Abeta40, and Abeta42/40 ratio cannot 
      distinguish T2DM-associated cognitive impairment from cognitive impairment. 
      Certain cytokines (YKL-40, NSE, and VEGF) have good performance in distinguishing 
      T2DM-associated cognitive impairment from simple cognitive impairment. Taken 
      together, this may improve the accuracy of the diagnosis and establishment of 
      individualized therapy.
FAU - Zhang, Weiwei
AU  - Zhang W
AD  - School of Medicine, Shandong University, Jinan, China.
AD  - Anhui Provincial Hospital, Shandong University, Hefei, China.
FAU - Liu, Yiming
AU  - Liu Y
AD  - Institute on Aging and Brain Disorders, First Affiliated Hospital of University 
      of Science and Technology of China, Hefei, China.
AD  - Neurodegenerative Disorder Research Center, Division of Life Sciences and 
      Medicine, University of Science and Technology of China, Hefei, China.
FAU - Bao, Hong
AU  - Bao H
AD  - Institute on Aging and Brain Disorders, First Affiliated Hospital of University 
      of Science and Technology of China, Hefei, China.
AD  - Neurodegenerative Disorder Research Center, Division of Life Sciences and 
      Medicine, University of Science and Technology of China, Hefei, China.
FAU - Zhang, Mengguo
AU  - Zhang M
AD  - Institute on Aging and Brain Disorders, First Affiliated Hospital of University 
      of Science and Technology of China, Hefei, China.
AD  - Neurodegenerative Disorder Research Center, Division of Life Sciences and 
      Medicine, University of Science and Technology of China, Hefei, China.
FAU - Gao, Feng
AU  - Gao F
AD  - Institute on Aging and Brain Disorders, First Affiliated Hospital of University 
      of Science and Technology of China, Hefei, China.
AD  - Neurodegenerative Disorder Research Center, Division of Life Sciences and 
      Medicine, University of Science and Technology of China, Hefei, China.
FAU - Kang, Dongmei
AU  - Kang D
AD  - Anhui Provincial Hospital, Shandong University, Hefei, China.
FAU - Shen, Yong
AU  - Shen Y
AD  - Institute on Aging and Brain Disorders, First Affiliated Hospital of University 
      of Science and Technology of China, Hefei, China.
AD  - Neurodegenerative Disorder Research Center, Division of Life Sciences and 
      Medicine, University of Science and Technology of China, Hefei, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Alzheimers Dis
JT  - Journal of Alzheimer's disease : JAD
JID - 9814863
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (Biomarkers)
RN  - 0 (Cytokines)
RN  - 0 (Peptide Fragments)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Amyloid beta-Peptides/blood
MH  - Biomarkers/blood
MH  - Cognitive Dysfunction/blood/*diagnosis/etiology
MH  - Cytokines/*blood
MH  - Diabetes Mellitus, Type 2/blood/*complications
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptide Fragments/blood
OTO - NOTNLM
OT  - Biomarkers
OT  - cognitive impairment
OT  - serum cytokines
OT  - type 2 diabetes mellitus
EDAT- 2020/04/07 06:00
MHDA- 2021/05/11 06:00
CRDT- 2020/04/07 06:00
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
PHST- 2020/04/07 06:00 [entrez]
AID - JAD200095 [pii]
AID - 10.3233/JAD-200095 [doi]
PST - ppublish
SO  - J Alzheimers Dis. 2020;75(2):461-469. doi: 10.3233/JAD-200095.